The expression and clinical significance of PD-1 in peripheral blood of hepatocellular carcinoma treated with m-TACE

Abstract

Abstract: Objective:To explore the changes and significance of CD4⁺programmed death receptor 1(PD-1) and CD8⁺PD-1 in peripheral blood after hepatocellular carcinoma(HCC) patient streated with microparticles transcatheter arterial chemoembolization(m-TACE).
Method:From 2021 to 2022, 20 patients with intermediate and advanced HCC with indications for m-TACE treatment were selected from the Hepatobiliary and Pancreatic Center of Beijing Tsinghua Chang Gung Hospital (HCC group), and 12 patients with non-alcoholic cirrhosis and 12 healthy volunteers were selected as cirrhosis group and healthy group. Flow cytometry was used to detect the expression of CD4⁺PD-1 and CD8⁺PD-1 in peripheral blood of healthy, cirrhotic, and liver cancer patients before and 1-2 weeks after m-TACE.
Result:The expression of CD4⁺/CD8⁺PD-1 in peripheral blood of the HCC group was significantly higher than that of the liver cirrhosis group and the healthy group. After 1-2 weeks of m-TACE, the expression of CD4⁺/CD8⁺PD-1 of HCC patients decreased compared to before treatment(P<0.05). Patients with good therapeutic effects after m-TACE have lower expression of CD4⁺/CD8⁺PD-1 in peripheral blood(P<0.05).
Conclusion:m-TACE treatment for HCC can reduce the expression of CD4⁺/CD8⁺PD-1 in peripheral blood.

Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Programmed death receptor 1, Immunotherapy

Ren Zhizhong, Yue Yuanxun, Wang Yaqin, Wang Yajing, Zhang Yuewei. The expression and clinical significance of PD-1 in peripheral blood of hepatocellular carcinoma treated with m-TACE[J]. Electronic Journal of Liver Tumor, 2023, 10(3): 48-51.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021, 71(3):209-249.
[2] KULIK L, EL-SERAG H B. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 6(2):477-491.
[3] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国抗癌协会肝癌专业委员会,北京医学会外科学分会肝脏学组,等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021 版)[J/CD].肝癌电子杂志, 2021, 8(2):6-15.
[4] 张跃伟,刘影.明胶海绵微粒经导管肝动脉化学治疗栓塞术对原发性肝癌疗效分析[J].中华肝脏病杂志, 2013, 21(8):637-638.
[5] LEONE P, SOLIMANDO A G, FASANO R, et al.The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment[J]. Vaccines (Basel) , 2021, 9(5):532.
[6] LENCIONI R, LLOVET J M.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1):52-60.
[7] LIU Y, ZHANG YW, BAUTISTA D, et al.Transarterial p53-gene-embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage B: single-centre experience[J]. Cell Biochem Biophys, 2015, 71(1):99-104.
[8] REN Z Z, YUE Y X, ZHANG Y W, et al.Changes in the peripheral blood treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles[J]. Front Immunol, 2021, 12:624789.
[9] YUE Y X, REN Z Z, LIU Y, et al.Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma[J]. J Interv Med, 2019, 2(1): 21-26.
[10] WU Y, LIN H, YOU X, et al.Immune checkpoint blockade in chinese patients with hepatocellular carcinoma: characteristics and particularity[J].Front Oncol, 2022, 12:764923.
[11] SORENSEN S F, ZHOU W, DOLLED-FILHART M, et al.PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy[J].Transl Oncol, 2016, 9(1): 64-69.
[12] 程小珍,李晓东,王顺兰,等.肝癌患者TACE 治疗前后外周血 PD-1、PD-L1 的表达及临床意义[J].中国现代医学杂志, 2019,29(3):33-37.
[13] MONTASSER A, BEAUFRÈRE A, CAUCHY F, et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma[J]. Histopathology, 2021, 79(1):36-46.

[1]	Miao Jixuan, Jin Yong. Progress of vascular intervention combined with targeted therapy and immunotherapy for hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 31-37.
[2]	Zhao Ying, Li Kewei, Yang Yanmei, Li Wei, Li Guangxin, Li Gong. Long-term outcomes of radiotherapy combined with immune checkpoint blockade inhibitor and lenvatinib therapy in hepatocellular carcinoma with portal vein tumor thrombus [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 58-63.
[3]	Wang Yu, Tong Liexing, Kang Wanying, Ding Xin, Qian Hesheng. Recognition of bone metastasis driving genes in hepatocellular carcinoma by machine learning and analysis of in external-beam radiotherapy [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 64-75.
[4]	Xin Lingxia, Xu Xin, Zhai Yirui, Deng Min, Chen Bo. The progress of radiotherapy in hepatocellular carcinoma with portal vein tumor thrombus [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 76-82.
[5]	Pan Wenbing, Lu Yao, Li Yan, Shi Zhuolin, Liu Yudi. Effect of narrative nursing model based on evidence-based medicine on early ambulation and compliance of patient [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 89-92.
[6]	Zhang Yixuan, Ma Yarui, Wang Xiaobing, Jiao Yuchen. Assay for transposase-accessible chromatin using sequencing combined with RNA sequencing to explore the effect of helicase like transcription factor deletion on hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2023, 10(2): 7-15.
[7]	Bian Tao, Qin Feng, Wang Shengjie, Wang Hui, Han Shanshan. Involvement of microRNA-551a in the response mechanism of sorafenib in patients with advanced hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2023, 10(2): 16-26.
[8]	Zhang Lisha, Kang Mingjia, Zhao Jian. Progress on the mechanism of lenvatinib resistance in hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2023, 10(2): 37-40.
[9]	Shen Yaqiong, Li Jiao, Li Xingxin, Xu Jing, Jin Yan. Research progress on the role of lysyl oxidase-like 2 in the development of hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2023, 10(2): 41-44.
[10]	Gu Xinglu, Zhao Xiaohang, Sun Yulin. The mechanism of histone deacetylase inhibitor vorinostat inhibiting the growth of hepatocellular carcinoma cells [J]. Electronic Journal of Liver Tumor, 2023, 10(1): 15-24.
[11]	Wang Yaning, Sheng Jiyao, Wang Zhenxiao, Zhang Xuewen. Progress on protein induced by vitamin K absence or antagonist-Ⅱ in the diagnosis and therapy of hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2023, 10(1): 39-44.
[12]	Li Changying, Xu Xin, Deng Min^*. Radiation therapy for hepatocellular carcinoma combined with systemic therapy [J]. Electronic Journal of Liver Tumor, 2022, 9(4): 15-19.
[13]	Li Lijuan, Dong Dezuo, Wang Hongzhi, Zhu Xianggao, Wang Weihu^*. Development and evidence of perioperative radiotherapy for hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2022, 9(4): 20-25.
[14]	Liu Ruifeng¹, Wang Dandan², Zhang Qiuning¹, Luo Hongtao³, Dong Meng², Wang Xiaohu^1,*. Efficacy and safety of particle therapy for hepatocellular carcinoma: a meta-analysis [J]. Electronic Journal of Liver Tumor, 2022, 9(4): 32-45.
[15]	Zhou Tengchao^*, Tian Zhuangbo, Long Lin. Efficacy and safety of sequential transcatheter arterial chemoembolization with ¹²⁵I seed strip combined with portal vein stent implantation guided by double guidance technology in the treatment of primary hepatocellular carcinoma complicated with portal vein tumor thrombus [J]. Electronic Journal of Liver Tumor, 2022, 9(4): 52-58.